Background: The International Prognostic Score (IPS) identifies seven independent factors predicting progression-free and overall survival in advanced stage Hodgkin's disease (HD). The IPS is also applicable in limited disease. However, the IPS does not identify patients with a very poor prognosis. The aim of this study was to define biological markers which may add to the IPS in predicting outcome.
Introduction
Current therapies fail to cure about one third of patients with advanced Hodgkin's disease (HD). However, longterm remissions and cure occur even in patients who stop treatment after two to four cycles of chemotherapy [1] . This may suggest over-treatment of an undefined fraction of patients with increasing risk of late complications such as secondary malignancies, cardiac toxicity and infertility [2] [3] [4] . In early stage disease, short-term chemotherapy is today commonly added to radiotherapy due to a high relapse rate among patients treated with the latter modality alone [5] [6] [7] [8] . The dose of radiotherapy is often reduced in these combined modality treatments with the hope of diminishing the late toxicity of irradiation [5, 6] . Thus, it is of great importance to identify additional markers, which may further characterise patients with a very dismal prognosis, who may benefit from aggressive upfront treatment, and, in addition, patients with a good prognosis, who can be given limited treatment without jeopardising outcome.
A number of mainly biological markers have been reported to predict outcome in the literature: Abnormal lymphocyte function [9] [10] [11] , C-reactive protein (CRP) [12] , serum levels of soluble (s)CD4 (Grimfors, data to be published), sCD8 [13, 14] , sCD25 [15] [16] [17] , sCD30 [14, 18 , Axdorph, data to be published], sCD54 [19, 20] , IL-10 [21] , p2-microglobulin ((32M) [22] , thymidine kinase (TK) [23] , IL-6 [24] and tumour necrosis factor (TNF) [25] . These biological markers were, for obvious reasons, not analysed in the International Prognostic Factors Project [26] . In that retrospective, multicenter project, 19 routinely documented demographic and clinical features were analysed at diagnosis in 1618 patients with HD receiving combination chemotherapy. Seven factors (age ^ 45 years, male sex, stage IV, albumin <40 g/1, haemoglobin (Hb) < 105 g/1, white blood cell (WBQ counts ^ 15 x 10 9 , lymphocyte counts <0.6 x 10 9 or <8% of WBC counts) related to poor progression-free and overall survival were combined to give a prognostic score, the IPS. This score is also applicable for HD patients with limited disease [27] . However, neither IPS nor previously published prognostic indices [28] allow the identification of a distinct group of patients with a very poor prognosis, defined as a five-year survival rate of < 50%. The aim of this study was to identify biological markers, which may add to the IPS in predicting outcome in HD for further validation in large, prospective studies.
Patients and methods

Biopsies and methods
The histopathology and immunophenotyping of biopsies were reviewed and, when necessary, complementary immunostainings for CD15, CD30, CD20, LN-1, CD79a, CD3, UCHL-1 and EMA (avidin-biotinperoxidase complex (ABC) technique) were performed to confirm the diagnosis. The R.E.A.L. Classification [29] was applied, including the division of nodular sclerosis (NS) according to the British National Lymphoma Investigation [30] .
Patient characteristics
In this retrospective study, 145 adults (>15 years) with previously untreated HD, diagnosed between 1974 and 1992, were included (Table 1) . Criteria for inclusion were known results of previous inves- 
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* Slides or biopsies were not available for review in three of these five cases.
tigations for serum markers [13, 16, 20] . The median age at diagnosis was 36 years (range 15-87 years) and the median follow-up for surviving patients was 143 months (range 44-272 months). The extent of disease was evaluated according to the Ann Arbor staging classification [31] with the following investigations: chest roentgenograms, radionuclide scanning of liver and spleen (1974) (1975) (1976) (1977) (1978) (1979) (1980) (1981) (1982) (1983) (1984) (1985) (1986) (1987) (1988) (1989) (1990) (1991) (1992) and bone (1975) (1976) (1977) (1978) (1979) (1980) (1981) (1982) (1983) (1984) (1985) (1986) (1987) (1988) (1989) (1990) (1991) (1992) and computed tomographic scanning (1977) (1978) (1979) (1980) (1981) (1982) (1983) (1984) (1985) (1986) (1987) (1988) (1989) (1990) (1991) (1992) of the abdomen and chest, when clinically indicated. Bone marrow involvement was assessed by bone marrow biopsies and aspirates. Bulky disease was defined as a mediastinal mass with a diameter exceeding one third of the maximal mediastinal width or any tumour manifestation with a diameter of > 10 cm. Complete remission (CR) corresponded to complete regression of all palpable or histologically documented tumours and resolution of all radiographic and biochemical abnormalities due to HD for a minimum of three months.
Treatment (Table 2) Details of treatment have been described previously [1, 11, 13, 32, 33] . In short, patients with limited disease (stage I-IIA) were given radiotherapy [11, 13, 32] . However, patients diagnosed 1974-1979 were included in a study regarding the value of early splenectomy. In this study, patients mainly in stage IIA-IIIA were given total nodal irradiation [33] . During this period, patients with stage IIIB-IV disease were given MOPP or CCNU-OPP chemotherapy [33] . From 1979, patients with stage IIB-IV disease received 6-8 cycles of MOPP/ ABVD chemotherapy with irradiation given to bulky disease [1] . All clinical and immunological studies were approved by the Ethics Committee at Karolinska Institutet and patients gave informed consent.
Biological markers
The analysed samples for each biological marker vary between 86 and 123 (Table 3) . Serum samples were collected before start of treatment and stored at -70 °C until use. Sera were collected prospectively, and were analysed on the same occasion. Serum levels of soluble markers were determined by means of commercially available sandwich immunoassay-methods: sCD4, sCD8 [13] , sCD25 [16] , sCD54 [20] (Cellfree® test kits, T-cell Science, Cambridge, Massachusetts), sCD30 (Dako CD30 (K.i-1 Antigen) ELISA) and IL-10 (Quantikine human IL-10, R&D Systems Europe). The minimal detectable value of IL-10 was 7.8 pg/ml. Thus, IL-10 was dichotomized at 10 pg/ml in accordance with Sarris et al. [21] . P2-microglobuhn (P2M) was analysed by a competitive luminometric assay (LIA-mat® p2-microglobulin, Cambridge Life Sciences pic). Thymidine kinase (TK.) was measured in a radio-enzyme assay (Prolifigen® TK-REA, AB Sangtec Medical).
Controls
The control population consisted of healthy blood donors and members of the laboratory staff. Patients had significantly higher median Stage I (n = 38) values than controls regarding sCD25 (P < 0.001,17 controls), sCD30 (P < 0.001,43 controls), f32M (/> < 0.001,79 controls),TK (P < 0.001, 160 controls), sCD54 (P = 0.054, 20 controls). The patient population did not statistically differ from controls with regard to IL-10 (8 controls), sCD4 (10 controls) and sCD8 (20 controls). CRP, Hb, WBC and total lymphocyte counts and albumin were determined according to standard methods.
Statistical methods
The Mann-Whitney U-test was used to calculate differences in distributions of serum markers between groups. All laboratory variables were initially analysed as continuous except IL-10, which was analysed as dichotomized only. In congruence with the IPS, Hb, WBC and total lymphocyte counts, albumin, age and stage were also dichotomized. Cut-off points were chosen according to the literature [21, 26] . When combining sCD30 with the IPS, sCD30 was dichotomized. The cutoff point for sCD30 was chosen as the median value. Data skewly distributed were logarithmically transformed. Linear regression and logistic regression analyses were used when analysing the association between year of diagnosis with the biological variables. Cause-specific survival (CSS) was defined as the time from diagnosis to death from HD or death related to treatment of the disease including second malignancies. Observations were censored by end of follow-up or death without signs of HD. In complete remitters, disease-free survival (DFS) was defined as the time from last day of treatment to relapse or death from HD or death related to treatment of the disease including second malignancies. Observations were censored by end of follow-up or death without signs of HD. Survival curves were constructed by the Kaplan-Meier procedure [34] . Differences in the survival for categorical factors were calculated by Gehan's Wilcoxon test [35] . Cox regression analyses were used for continuous factors univariately and for the multivariate analyses [36] . In the latter analysis, only markers, significant in univariate analyses, with less than 15% missing values, were analysed. Thus, serum levels of sCD25, sCD30 and CRP were not analysed with respect to their independent significance.
Results
At follow-up, 57 patients had died. Forty patients died from progressive HD or from complications to the treatment including three patients, who developed myelodysplastic syndrome/acute leukaemia. The year of diagnosis was not associated with CSS or DFS (data not shown). The CR rate was 86%. Thirty-eight of the one hundred twenty-five patients (30%) who achieved a CR relapsed during the observation period. In the whole series, the five-year CSS was 82%. Among patients achieving a CR, the five-year DFS was 69%. 
Cause-specific survival
Evaluation of the International Prognostic Score Low serum albumin (P < 0.001), anaemia (P < 0.001), stage IV (P = 0.003), age ^ 45 years (P = 0.006), low lymphocyte counts (P -0.020) but not male sex and increased WBC counts predicted a poor CSS in univariate analyses. In the multivariate analysis of IPS factors reaching significance in univariate analyses, albumin (P = 0.007), Hb (P = 0.026) and stage (P = 0.041) retained significance with a borderline value for age (P -0.053). In the multivariate analysis of IPS factors, 143 patients were analysed. Two patients had missing data regarding albumin and total lymphocyte count, respectively. High-risk patients (score 3-7) had a significantly worse survival as compared to low-risk patients (score 0-2, P < 0.001, Figure 1 ).
Biological markers
Increased serum levels of sCD30 (P < 0.001), CRP (P < 0.001) and sCD25 (P -0.010) as well as serum IL-10 ^ 10 pg/ml (P < 0.001) predicted a poor CSS in univariate analyses. The predicted prognostic capacity of serum levels of sCD4, sCD8, sCD54, p"2M and TK did not reach statistical significance. We did as well perform survival analyses with control for year of diagnosing. Controlling for this factor did not change the results (data not shown). In the multivariate analysis including significant factors from the IPS, IL-10 retained an independent prognostic significance ( Table 4) . For IL-10, controlling for Hb and albumin, the hazards were not different for the two values considered as judged by log minus log plots (data not shown).
Serum IL-10, sCD30 and the International Prognostic Factor Score
Patients were subgrouped according to IPS and dichotomized serum IL-10 values (P < 0.001, Figure 2 ). IL-10 No of patients 38 22 9 24 Five-year survival 97% 77% 89% 54%
Ten-year survival 91% 77% 89% 30% score 0-2 and sCD30 <40 U/mL: score 0-2 and sCD30 >40 U/mL score 3-7 and sCD30 <40 U/ mLscore 3-7 and sCD30 >40 U/mL added prognostic information to that achieved by the IPS: patients with a high score and increased IL-10 levels had a very poor outcome with a five-year CSS of 38%, while patients with a low score and low IL-10 levels had a five-year CSS of 91%. At five years, the CSS did nor differ in patients with low score and high and low IL-10 levels, respectively. However, the 10-year CSS was 43% for patients with a low score and increased IL-10 levels as compared to 88% for patients with a low score and low IL-10 levels. Subgrouping according to IPS and dichotomized serum sCD30 values showed a five-year CSS for patients with a high score and increased sCD30 levels of 54%, being significantly worse than that of other subgroups (P < 0.001, Figure 3) . 
Disease-free survival Evaluation of the International Prognostic Factor Score
Increased WBC counts (P -0.014) predicted a poor DFS in univariate analysis. Low levels of albumin, anaemia, stage IV, age ^45 years, low lymphocyte counts or male sex did not reach statistical significance.
Biological markers
Increased serum levels of sCD25 (P = 0.009), sCD30 (P = 0.028), CRP (P = 0.034) and sCD8 (P = 0.051) predicted a poor DFS in univariate analyses, as well as serum IL-10 ^ 10 pg/ml {P -0.010). The prognostic discriminatory capacity of serum levels of sCD4, sCD54, P2M, TK did not reach statistical significance. Serum IL-10 had an independent impact on DFS in the multivariate analysis (P = 0.007) with the WBC count of the IPS as a competing factor.
Discussion
In spite of considering established prognostic factors such as age, stage, haemoglobin values and others, there is a great variability in outcome of patients with advanced stage HD. The search for additional prognostic factors has been intensive for many years. The aim has been to identify patients with a very poor prognosis, who may benefit from aggressive upfront treatment. Also, to find patients, who can be treated less aggressively without compromising the anti-tumour effect, but with less acute and late toxic complications. Recently, Sarris et al. reported that serum levels of IL-10 was a strong biological prognostic factor [21] , and other groups have described the same results [37, 38] .
In limited disease, high relapse rates after radiotherapy alone have led to the use of a combination of chemotherapy and radiotherapy in many centres. It is likely, that this approach will lead to over-treatment of some patients, increasing the incidence of late complications. Thus, apt predictors of prognosis are of equal importance in patients with limited disease. Previously known prognostic factors have been included in different prognostic indices for survival [28] , but these indices have failed to identify patients at very high risk. An important work was the IPS study, where seven factors related to progression-free and overall survival in HD patients receiving combination chemotherapy were identified [26] . Interestingly, some of the previously known variables, among them extranodal disease, histologic type, erythrocyte sedimentation rate, were found not to add prognostic information in that study. This may in part be due to an improved success rate during recent years. The score predicted five-year rates of freedom from progression of disease in the range of 42% to 84%, and 56% to 89% in overall survival. Thus, even this prognostic score could not identify a subgroup of patients with a very poor prognosis (a five-year survival < 50%) and a potential need of more aggressive upfront treatment.
Despite the limited number of patients included in the present study, the results were in a good accordance with those of the IPS study: five of the seven factors significantly predicted a poor CSS in univariate analyses, and four factors remained in the multivariate analysis. A very good prognostic discriminatory capacity was also seen, when the patients where divided into a low-risk and a high-risk group (score 0-2 and 3-7, respectively). Fifty-seven patients (38%) in our study had limited disease (stage I-IIA, treated with radiotherapy alone). In comparison, the inclusion criterion in the international study was advanced disease, treated with chemotherapy ± radiotherapy. However, Franklin et al. has reported that the IPS also is applicable for patients with limited disease [27] . We analysed CSS as end point instead of freedom from progression, which was the main end point reported in the IPS study. In agreement with Jack et al. [39] , who also evaluated the score with CSS, we find CSS to constitute a definitive measure of failure. In addition, we also analysed prognostic factors in relation to DFS. An important factor to consider with regard to DFS is the greater risk of relapse following radiotherapy alone [6] . However, we found no difference in time to relapse or disease-free survival among CR patients according to initial treatment (radiotherapy, chemotherapy or combined modality treatment; data not shown). In the IPS study, analyses were restricted to patients between 15 and 65 years. In the search for prognostic variables, that will help the clinician in individualising treatment, we find it important not to exclude older patients. Optimising treatment in older patients with intercurrent diseases constitutes a major therapeutic challenge. To avoid misinterpretation of survival because of intercurrent diseases, we analysed cause-specific survival. In conclusion: in spite of a restricted number of patients, inclusion of patients of all ages and stages and the use of other end points, this patient population showed a good concordance with the results of the IPS study.
A useful prognostic marker has to be 1) easy to analyse and 2) show reliable reproducibility, and of course, be a strong predictor of prognosis, identifiable also in smaller groups of patients. In a series of previous reports we have evaluated biological markers relevant for HD with the goal to refine our ability to predict prognosis [9-11, 13, 16, 20] . There are certain other variables, for example IL-6 and TNF/TNF-receptors, that would also be of interest to evaluate in association to IPS [24, 25] . However, this is already a rather variable intense study, and we had to limit the number of variables. Partly due to the same reason, we did not include blood lymphocyte function tests, although these have in previous studies been shown to be a strong predictor of prognosis [9] [10] [11] . In addition, tests of lymphocyte function are rather complex, and their reproducibility may be questioned. In order to address the issue whether cytokine levels remain stable during storage at -70 °C over several years, we tested the association between year of diagnosis with CRP, IL-10 and with the log values of sCD4, sCD8, sCD25, sCD30, sCD54, P2M and TK. sCD4, sCD54, 02M and TK showed positive association with calendar time on 5% risk level. As a consequence of this, we repeated all survival analyses with control for year of diagnosis. However, the overall results where not changed (data not shown).
The univariate analyses regarding the significant correlations of a poor CSS and increased serum levels of IL-10, sCD30, sCD25 and CRP confirmed results of previous studies concerning biological markers and prognosis [12, 14-16, 18, 21, 37, 38] . In the multivariate analysis, IL-10 emerged as an independent variable, which is also in agreement with previous studies [21, 37, 38] . IL-10 seems to be helpful in adding prognostic information to that achieved by the IPS: patients with a high score and increased IL-10 had a very poor outcome, patients with a low score and low levels of IL-10 had a good prognosis, and patients with the combination of a low score and high IL-10 as well as a high score and low IL-10 showed an intermediate pattern. In addition, a high serum level of IL-10 also predicted a poor DFS. Patients with the combination of high serum levels of sCD30 and a high score according to IPS also had a poor prognosis.
Serum levels of sCD25, sCD30 and CRP were not analysed with respect to their independent significance because of > 15% missing data.
We conclude that IL-10 and sCD30 may add to prediction of outcome in HD, and thereby be helpful in identifying high-and low-risk patients with the goal to optimise treatment. Hopefully these results will encourage others to measure biological factors such as IL-10 and sCD30 in order to allow a future multivariate analysis in a substantial number of patients.
